skip to primary navigationskip to content

GeneAdviser partners with Birmingham Women’s Hospital to make personalised medicine more accessible

last modified Sep 29, 2016 10:46 AM
The largest genetics laboratory in the NHS brings to the platform their solid tumour sequencing, enabling clinicians to give an individual approach to their patients, tailored to their tumour’s genetic makeup.
GeneAdviser partners with Birmingham Women’s Hospital to make personalised medicine more accessible

 GeneAdvisor's CEO Jelena Aleksic (left) and CTO Robert Stojnic (right)

GeneAdviser is bringing the expertise of Birmingham Women’s Hospital to their ordering platform, where healthcare professionals can now order tests for genetic sequencing of tumour samples, screening for those changes in the tumour that may require clinical action.

Each tumour has a different genetic makeup, which makes it react to therapies very differently. By analysing and monitoring the presence of genetic sequences in a tumour, patients can be prescribed more targeted treatment and screening.

Dr Jelena Aleksic, GeneAdviser’s CEO, commented: “Birmingham Women’s Hospital combines outstanding and comprehensive genetics research and clinical expertise, making it an internationally renowned clinical laboratory. We are delighted to make their excellent genetic testing more accessible to doctors worldwide, helping them provide better care for their patients.”

Professor Michael Griffiths, the Birmingham Women’s Hospital Genetics Laboratory Director, added: "We are excited to join forces with GeneAdviser to facilitate worldwide access to our genetic test portfolio.  As the largest NHS genetics laboratory we already work closely with clinicians across the UK and internationally, and GeneAdviser will allow them to easily order the genetic  tests they need for their patients, whilst streamlining administrative processes for our staff."

Their partnership also expands beyond solid tumour sequencing, bringing forward a selection of high quality genetic tests in oncology and other medical specialties. Other tests from Birmingham Women’s Hospital include their Lucina NIPT (non invasive prenatal testing), a highly accurate genetic prenatal testing that screens for trisomies such as Down syndrome using a single maternal blood sample.

RSS Feed Latest news

ideaSpace Alumni close three funding deals in a week

Jun 26, 2017

£4.3m raised in an exceptional 7 days for SyndicateRoom

Life sciences equity crowdfunding platform, Capital Cell shortlisted for international award

Jun 23, 2017

Shortlisted for the Best International Growth Business award at the UK Business Angels Association Investment Awards 2017

Addenbrooke's takes over the GeneAdviser ordering platform for genetic testing

Jun 21, 2017

GeneAdviser's platform to live on as in-house NHS tool

Capital Cell's UK Equity investment platform is now up and running!

Jun 02, 2017

Cutting edge life science investments with potentially huge financial rewards

PragmatIC named Future Planet “Company of the Year”

May 26, 2017

Award recognises PragmatIC's potential not only revolutionise the electronics market, but change the world.

View all news